LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Breakthrough omicron COVID-19 infections in patients receiving the REGEN-Cov antibody combination.

    Flahault, Adrien / Touchard, Justine / Péré, Hélène / Ulrich, Laetitia / Sabatier, Brigitte / Veyer, David / Lebeaux, David / Thervet, Eric

    Kidney international

    2022  Volume 101, Issue 4, Page(s) 824–825

    MeSH term(s) Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; COVID-19 ; COVID-19 Vaccines/adverse effects ; Drug Combinations ; Humans
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; COVID-19 Vaccines ; Drug Combinations ; casirivimab and imdevimab drug combination
    Language English
    Publishing date 2022-02-12
    Publishing country United States
    Document type Letter
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2022.01.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.

    Touchard, Justine / Perrin, G / Berdot, S / Pouchot, J / Loustalot, M C / Sabatier, B

    European journal of clinical pharmacology

    2020  Volume 77, Issue 2, Page(s) 189–195

    Abstract: Purpose: Although more practical for use, the impact of ferric carboxymaltose (FCM) on the hospital budget is considerable, and intravenous iron sucrose complex (ISC) represents a cost-saving alternative for the management of iron deficiency anemia in ... ...

    Abstract Purpose: Although more practical for use, the impact of ferric carboxymaltose (FCM) on the hospital budget is considerable, and intravenous iron sucrose complex (ISC) represents a cost-saving alternative for the management of iron deficiency anemia in patients during hospitalization. The Drug Committee decided to reserve FCM for day hospitalizations and contraindications to ISC, especially allergy. ISC was available for prescription for all other situations.
    Methods: The impact of a multifaceted intervention promoting a switch from FCM to ISC was evaluated using an interrupted time series model with segmented regression analysis. The standardized rate of the dispensing of FCM, ISC, and oral iron by the hospital pharmacy, as well as the rate of the dispensing of packed red blood cells and the number of biological iron status measurements, was analyzed before and after the intervention.
    Results: There was an immediate decrease in FCM consumption following the intervention, with a reduction of 88% (RR: 0.12 [CI
    Conclusion: Our intervention to lower the impact of intravenous iron therapy on the hospital budget was effective.
    MeSH term(s) Administration, Oral ; Anemia, Iron-Deficiency/blood ; Anemia, Iron-Deficiency/diagnosis ; Anemia, Iron-Deficiency/drug therapy ; Anemia, Iron-Deficiency/economics ; Cost Savings/statistics & numerical data ; Cost-Benefit Analysis/organization & administration ; Cost-Benefit Analysis/statistics & numerical data ; Decision Support Systems, Clinical/economics ; Decision Support Systems, Clinical/organization & administration ; Drug Prescriptions/economics ; Drug Prescriptions/statistics & numerical data ; Ferric Compounds/administration & dosage ; Ferric Compounds/economics ; Ferric Oxide, Saccharated/administration & dosage ; Ferric Oxide, Saccharated/economics ; France ; Health Plan Implementation ; Hematinics/administration & dosage ; Hematinics/economics ; Hospital Costs/statistics & numerical data ; Hospitalization/economics ; Humans ; Infusions, Intravenous/economics ; Interrupted Time Series Analysis ; Iron/blood ; Maltose/administration & dosage ; Maltose/analogs & derivatives ; Maltose/economics ; Pharmacy Service, Hospital/economics ; Pharmacy Service, Hospital/organization & administration ; Pharmacy Service, Hospital/statistics & numerical data ; Program Evaluation ; Treatment Outcome
    Chemical Substances Ferric Compounds ; Hematinics ; ferric carboxymaltose (6897GXD6OE) ; Maltose (69-79-4) ; Iron (E1UOL152H7) ; Ferric Oxide, Saccharated (FZ7NYF5N8L)
    Language English
    Publishing date 2020-09-14
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 121960-1
    ISSN 1432-1041 ; 0031-6970
    ISSN (online) 1432-1041
    ISSN 0031-6970
    DOI 10.1007/s00228-020-02993-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Psychometric Properties of a Machine Learning-Based Patient-Reported Outcome Measure on Medication Adherence: Single-Center, Cross-Sectional, Observational Study.

    Korb-Savoldelli, Virginie / Tran, Yohann / Perrin, Germain / Touchard, Justine / Pastre, Jean / Borowik, Adrien / Schwartz, Corine / Chastel, Aymeric / Thervet, Eric / Azizi, Michel / Amar, Laurence / Kably, Benjamin / Arnoux, Armelle / Sabatier, Brigitte

    Journal of medical Internet research

    2023  Volume 25, Page(s) e42384

    Abstract: Background: Medication adherence plays a critical role in controlling the evolution of chronic disease, as low medication adherence may lead to worse health outcomes, higher mortality, and morbidity. Assessment of their patients' medication adherence by ...

    Abstract Background: Medication adherence plays a critical role in controlling the evolution of chronic disease, as low medication adherence may lead to worse health outcomes, higher mortality, and morbidity. Assessment of their patients' medication adherence by clinicians is essential for avoiding inappropriate therapeutic intensification, associated health care expenditures, and the inappropriate inclusion of patients in time- and resource-consuming educational interventions. In both research and clinical practices the most extensively used measures of medication adherence are patient-reported outcome measures (PROMs), because of their ability to capture subjective dimensions of nonadherence. Machine learning (ML), a subfield of artificial intelligence, uses computer algorithms that automatically improve through experience. In this context, ML tools could efficiently model the complexity of and interactions between multiple patient behaviors that lead to medication adherence.
    Objective: This study aimed to create and validate a PROM on medication adherence interpreted using an ML approach.
    Methods: This cross-sectional, single-center, observational study was carried out a French teaching hospital between 2021 and 2022. Eligible patients must have had at least 1 long-term treatment, medication adherence evaluation other than a questionnaire, the ability to read or understand French, an age older than 18 years, and provided their nonopposition. Included adults responded to an initial version of the PROM composed of 11 items, each item being presented using a 4-point Likert scale. The initial set of items was obtained using a Delphi consensus process. Patients were classified as poorly, moderately, or highly adherent based on the results of a medication adherence assessment standard used in the daily practice of each outpatient unit. An ML-derived decision tree was built by combining the medication adherence status and PROM responses. Sensitivity, specificity, positive and negative predictive values (NPVs), and global accuracy of the final 5-item PROM were evaluated.
    Results: We created an initial 11-item PROM with a 4-point Likert scale using the Delphi process. After item reduction, a decision tree derived from 218 patients including data obtained from the final 5-item PROM allowed patient classification into poorly, moderately, or highly adherent based on item responses. The psychometric properties were 78% (95% CI 40%-96%) sensitivity, 71% (95% CI 53%-85%) specificity, 41% (95% CI 19%-67%) positive predictive values, 93% (95% CI 74%-99%) NPV, and 70% (95% CI 55%-83%) accuracy.
    Conclusions: We developed a medication adherence tool based on ML with an excellent NPV. This could allow prioritization processes to avoid referring highly adherent patients to time- and resource-consuming interventions. The decision tree can be easily implemented in computerized prescriber order-entry systems and digital tools in smartphones. External validation of this tool in a study including a larger number of patients with diseases associated with low medication adherence is required to confirm its use in analyzing and assessing the complexity of medication adherence.
    MeSH term(s) Adult ; Humans ; Adolescent ; Psychometrics ; Artificial Intelligence ; Cross-Sectional Studies ; Medication Adherence ; Machine Learning ; Patient Reported Outcome Measures
    Language English
    Publishing date 2023-10-16
    Publishing country Canada
    Document type Observational Study ; Journal Article
    ZDB-ID 2028830-X
    ISSN 1438-8871 ; 1438-8871
    ISSN (online) 1438-8871
    ISSN 1438-8871
    DOI 10.2196/42384
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Formulation and Stability of Ataluren Eye Drop Oily Solution for Aniridia.

    Djayet, Celia / Bremond-Gignac, Dominique / Touchard, Justine / Secretan, Philippe-Henri / Vidal, Fabrice / Robert, Matthieu P / Daruich, Alejandra / Cisternino, Salvatore / Schlatter, Joël

    Pharmaceutics

    2020  Volume 13, Issue 1

    Abstract: Congenital aniridia is a rare and severe panocular disease characterized by a complete or partial iris defect clinically detectable at birth. The most common form of aniridia occurring in around 90% of cases is caused by PAX6 haploinsufficiency. The ... ...

    Abstract Congenital aniridia is a rare and severe panocular disease characterized by a complete or partial iris defect clinically detectable at birth. The most common form of aniridia occurring in around 90% of cases is caused by PAX6 haploinsufficiency. The phenotype includes ptosis, nystagmus, corneal limbal insufficiency, glaucoma, cataract, optic nerve, and foveal hypoplasia. Ataluren eye drops aim to restore ocular surface PAX6 haploinsufficiency in aniridia-related keratopathy (ARK). However, there are currently no available forms of the ophthalmic solution. The objective of this study was to assess the physicochemical and microbiological stability of ataluren 1% eye drop in preservative-free low-density polyethylene (LDPE) bottle with an innovative insert that maintains sterility after opening. Because ataluren is a strongly lipophilic compound, the formulation is complex and involves a strategy based on co-solvents in an aqueous phase or an oily formulation capable of totally dissolving the active ingredient. The visual aspect, ataluren quantification by a stability-indicating chromatographic method, and microbiological sterility were analyzed. The oily formulation in castor oil and DMSO (10%) better protects ataluren hydrolysis and oxidative degradation and permits its complete solubilization. Throughout the 60 days period, the oily solution in the LDPE bottle remained clear without any precipitation or color modification, and no drug loss and no microbial development were detected. The demonstrated physical and microbiological stability of ataluren 1% eye drop formulation at 22-25 °C might facilitate clinical research in aniridia.
    Language English
    Publishing date 2020-12-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527217-2
    ISSN 1999-4923
    ISSN 1999-4923
    DOI 10.3390/pharmaceutics13010007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Stability of Pentobarbital Hydrogel for Rectal Administration in Pediatric Procedural Sedation.

    Belo, Sephora / Touchard, Justine / Secretan, Philippe-Henri / Vidal, Fabrice / Boudy, Vincent / Cisternino, Salvatore / Schlatter, Joël

    Hospital pharmacy

    2020  Volume 56, Issue 4, Page(s) 332–337

    Abstract: Purpose: ...

    Abstract Purpose:
    Language English
    Publishing date 2020-01-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1468893-1
    ISSN 0018-5787
    ISSN 0018-5787
    DOI 10.1177/0018578719901276
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.

    Nguyen, Yann / Flahault, Adrien / Chavarot, Nathalie / Melenotte, Cléa / Cheminant, Morgane / Deschamps, Paul / Carlier, Nicolas / Lafont, Emmanuel / Thomas, Marion / Flamarion, Edouard / Lebeaux, David / Charlier, Caroline / Rachline, Anne / Guérin, Corinne / Ratiney, Robert / Touchard, Justine / Péré, Hélène / Rozenberg, Flore / Lanternier, Fanny /
    Arlet, Jean-Benoît / Avouac, Jérôme / Boussaud, Véronique / Guillemain, Romain / Vignon, Marguerite / Thervet, Eric / Scemla, Anne / Weiss, Laurence / Mouthon, Luc

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

    2022  Volume 28, Issue 12, Page(s) 1654.e1–1654.e4

    Abstract: Objective: Immunocompromised patients have an increased risk of a severe form of COVID-19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as pre-exposure prophylaxis against BA.1 and BA.2 SARS-CoV-2 Omicron ... ...

    Abstract Objective: Immunocompromised patients have an increased risk of a severe form of COVID-19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as pre-exposure prophylaxis against BA.1 and BA.2 SARS-CoV-2 Omicron sublineages is unknown. We aimed to describe the incidence and outcomes of COVID-19 among immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis during the Omicron wave in France.
    Methods: This was an observational multicentre cohort study of immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis between December 28, 2021 and March 31, 2022. Patients received tixagevimab/cilgavimab 150/150 mg intramuscularly if they had impaired vaccine response and a high risk of severe form of COVID-19.
    Results: Tixagevimab/cilgavimab was administered to 1112 immunocompromised patients. After a median (range) follow-up of 63 (49-73) days, COVID-19 was confirmed in 49/1112 (4.4%) ≥5 days after treatment. During the study period, mean weekly incidence rate was 1669 in 100 000 inhabitants in Ile-de-France and 530 in 100 000 among patients who received tixagevimab/cilgavimab prophylaxis. Among infected patients, 43/49 (88%) had a mild-to-moderate form and 6/49 (12%) had a moderate-to-severe form of COVID-19. Patients with moderate-to-severe illnesses were less likely to have received early therapies than patients with mild forms (53.5% vs. 16.7% respectively) and 2/49 (4%) patients died from COVID-19.
    Discussion: Our study reported a low rate of infections and severe illnesses among immunocompromised patients treated with tixagevimab/cilgavimab. A global preventive strategy including vaccines, preexposure prophylaxis with monoclonal antibodies, and early therapies might be effective to prevent severe forms of COVID-19 among severely immunocompromised patients.
    MeSH term(s) Humans ; COVID-19/drug therapy ; COVID-19/prevention & control ; Pre-Exposure Prophylaxis ; SARS-CoV-2 ; Cohort Studies ; Immunocompromised Host ; Antibodies, Monoclonal
    Chemical Substances tixagevimab ; cilgavimab (1KUR4BN70F) ; Antibodies, Monoclonal
    Language English
    Publishing date 2022-08-01
    Publishing country England
    Document type Observational Study ; Journal Article
    ZDB-ID 1328418-6
    ISSN 1469-0691 ; 1470-9465 ; 1198-743X
    ISSN (online) 1469-0691
    ISSN 1470-9465 ; 1198-743X
    DOI 10.1016/j.cmi.2022.07.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top